Myriad Genetics, Inc. [NASDAQ:MYGN]: Analyst Rating and Earnings
Equities traders frequently stay up to date regarding what leading market analysts think about a possible stock buy. As it relates to Myriad Genetics, Inc. [MYGN], the latest mean analyst recommendation that’s publicly available is from the fiscal three-month period ending in June. On average, stock market experts give MYGN an Hold rating. Its stock price has been found in the range of 57.33 to 77.13. This is compared to its latest closing price of $29.25.
Wall Street analysts provide their ratings on a scale of 1 to 5, and the current average score for Myriad Genetics, Inc. [MYGN] is sitting at 2.54. This is compared to 1 month ago, when its average rating was 2.54.
For the quarter ending in Dec-18 Myriad Genetics, Inc. [MYGN] generated $0.22 billion in sales. That’s 0.03% higher than the average estimate of $0.22 billion as provided by Wall Street analysts. The three indicators above suggest that overall, this stock is demonstrating a mixed bag of positive appeal and some drawbacks, making it a somewhat risky investment that also has the potential to generate high ROI in the long run.
Stay on the lookout for the next quarterly financial report – the company is expected to release the following results on Tue 14 May (In 90 Days).
Fundamental Analysis of Myriad Genetics, Inc. [MYGN]
Now let’s turn to look at profitability: with a current Operating Margin for Myriad Genetics, Inc. [MYGN] sitting at +7.44 and its Gross Margin at +77.06, this company’s Net Margin is now 2.50%. These metrics indicate that this company is not generating as much profit, after accounting for expenses, compared to its market peers.
This company’s Return on Total Capital is 6.21, and its Return on Invested Capital has reached 10.30%. Its Return on Equity is 15.04, and its Return on Assets is 10.31. These metrics suggest that this Myriad Genetics, Inc. does a poor job of managing its assets, and likely won’t be able to provide successful business outcomes for its investors in the near term.
Turning to investigate this organization’s capital structure, Myriad Genetics, Inc. [MYGN] has generated a Total Debt to Total Equity ratio of 0.96. Similarly, its Total Debt to Total Capital is 0.95, while its Total Debt to Total Assets stands at 0.76. Looking toward the future, this publicly-traded company’s Long-Term Debt to Equity is 0.96, and its Long-Term Debt to Total Capital is 0.95.
What about valuation? This company’s Enterprise Value to EBITDA is 17.71 and its Total Debt to EBITDA Value is 0.08. The Enterprise Value to Sales for this firm is now 2.44, and its Total Debt to Enterprise Value stands at 0.00. Myriad Genetics, Inc. [MYGN] has a Price to Book Ratio of 2.73, a Price to Cash Flow Ratio of 23.22 and P/E Ratio of 83.75. These metrics suggest that this publicly-traded organization will not likely result in investment gains.
Shifting the focus to workforce efficiency, Myriad Genetics, Inc. [MYGN] earns $321,917 for each employee under its payroll. Similarly, this company’s Receivables Turnover is 7.24 and its Total Asset Turnover is 0.61. This publicly-traded organization’s liquidity data is also interesting: its Quick Ratio is 2.86 and its Current Ratio is 3.19. This company, considering these metrics, has a healthy ratio between its short-term liquid assets and its short-term liabilities, making it a less risky investment.
Let’s now turn our attention to trading performance: Myriad Genetics, Inc. [MYGN] has 74.20M shares outstanding, amounting to a total market cap of $2.26B. Its stock price has been found in the range of 26.05 to 50.44. At its current price, it has moved by -39.49% from its 52-week high, and it has moved 17.16% from its 52-week low.
This stock’s Beta value is currently 0.55, which indicates that it is more volatile that the wider market. This stock’s Relative Strength Index (RSI) is at 57.91. This RSI score is good, suggesting this stock is neither overbought or oversold.
Conclusion: Is Myriad Genetics, Inc. [MYGN] a Reliable Buy?
Myriad Genetics, Inc. [MYGN] stock is presenting a less attractive investment opportunity when compared to similarly-sized corporations in the same industry. The price performance of these shares has not shown much promise, and the financial results that this company has recently delivered present a highly risky investment.